Diffuse large B-cell lymphoma (DLBCL) is a cancer of B cells, a type of lymphocyte that is responsible for producing antibodies.

2025年1月6日 · Diffuse large B-cell lymphoma (DLBCL) is a fast-growing blood cancer that affects your lymphatic system. Healthcare providers typically treat it with a combination of cancer …

2023年3月24日 · Diffuse large B-cell lymphoma, or DLBCL, is a cancer that starts in white blood cells called lymphocytes. It usually grows in lymph nodes -- the pea-sized glands in your neck, groin,...

2021年5月1日 · Diffuse large B cell lymphoma (DLBCL), the most common type of Non-Hodgkin lymphoma (NHL), comprises a heterogeneous group of diseases with different biology, clinical presentations, and response to treatment.

Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of non-Hodgkin’s lymphoma that arises from the germinal center. It represents a heterogeneous disease characterized by different pathological, clinical, and molecular entities.

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the United States and worldwide, accounting for about 22 percent of newly diagnosed cases of B-cell NHL in the United States. More than 18,000 people are …

Diffuse large B cell lymphoma (DLBCL), the most common type of Non-Hodgkin lymphoma (NHL), comprises a heterogeneous group of diseases with different biology, clinical presentations, and response to treatment.

2021年3月3日 · DLBCL, an aggressive cancer, accounts for about 30% of all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially, with another 20 to 25% cured with salvage therapy.

2024年3月4日 · Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma, diagnosed in more than 18,000 people in the U.S. every year. It is a fast-growing …

4 天之前 · Diffuse large B-cell lymphoma (DLBC) is the most prevalent subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 30–40% of all NHL cases worldwide [1, 2]. DLBC is characterized by aggressive tumor growth and clinical heterogeneity, resulting in varied patient outcomes [3]. Despite the introduction of the standard immunochemotherapy regimen, R-CHOP (rituximab, cyclophosphamide ...